Nisa Investment Advisors LLC Lowers Position in LivaNova PLC (NASDAQ:LIVN)

Nisa Investment Advisors LLC lowered its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 46.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,066 shares of the company's stock after selling 15,642 shares during the quarter. Nisa Investment Advisors LLC's holdings in LivaNova were worth $949,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Fifth Third Bancorp increased its holdings in shares of LivaNova by 97.1% in the second quarter. Fifth Third Bancorp now owns 674 shares of the company's stock valued at $37,000 after purchasing an additional 332 shares during the period. Hexagon Capital Partners LLC increased its holdings in LivaNova by 117.8% in the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company's stock worth $37,000 after buying an additional 370 shares during the period. Lazard Asset Management LLC purchased a new position in LivaNova during the 1st quarter worth approximately $84,000. Canada Pension Plan Investment Board acquired a new stake in LivaNova during the 2nd quarter valued at approximately $88,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of LivaNova in the 1st quarter valued at $94,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have commented on LIVN shares. Mizuho lowered their price target on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating on the stock in a report on Thursday. The Goldman Sachs Group initiated coverage on LivaNova in a research report on Friday, October 4th. They set a "buy" rating and a $65.00 price target for the company. Robert W. Baird raised their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an "outperform" rating in a research note on Thursday. Stifel Nicolaus upped their price target on LivaNova from $70.00 to $72.00 and gave the stock a "buy" rating in a report on Thursday, July 25th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $75.00 price target on shares of LivaNova in a report on Thursday. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, LivaNova presently has a consensus rating of "Buy" and an average price target of $69.17.

LivaNova Price Performance

LIVN traded down $2.12 on Monday, hitting $49.01. 818,788 shares of the company's stock were exchanged, compared to its average volume of 622,562. LivaNova PLC has a fifty-two week low of $42.75 and a fifty-two week high of $64.47. The stock has a market cap of $2.66 billion, a price-to-earnings ratio of 121.74 and a beta of 1.01. The firm has a 50-day moving average price of $51.13 and a 200-day moving average price of $53.13. The company has a current ratio of 3.37, a quick ratio of 2.94 and a debt-to-equity ratio of 0.49.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.